Needham analyst Joshua Reilly downgrades ChannelAdvisor (NYSE:ECOM) from Buy to Hold.
SVB Leerink Maintains Outperform on BridgeBio Pharma, Lowers Price Target to $19
SVB Leerink analyst Mani Foroohar maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and lowers the price target from $23 to $19.